+ Employee Stock Options Plan
More information about location
Accelerating drug time-to-market
Job no longer available
Accelerating drug time-to-market
1-20 employees
Job no longer available
+ Employee Stock Options Plan
More information about location
1-20 employees
To empower researchers and regulators to analyse and monitor studies transparently in real-time, leading to improved and safer therapies for devastating diseases.
Desirable
Drug development times are painfully long, with patients waiting years upon years for new medicines to hit the market. Verisian is hoping to change this, with a range of tools to facilitate faster drug trialling and analysis of results.
The company's products target know pain-points in the clinical trial pipeline. For example, Verisian Builder allows trials to be designed faster by supplying a library of pre-approved modules based on existing studies. Trials can be pooled for analysis with Verisian Pooler, while data can be extracted and virtualised with Verisian Tracer.
Verisian is advancing its mission to streamline clinical trails with the release of its first product, Validator, which traces data lineage in SAS outputs to support automated study validation. Now, the team is focused on developing Builder, an AI-powered tool for designing and validating studies, while expanding partnerships with tier-1 pharmaceutical companies.
Kirsty
Company Specialist at Welcome to the Jungle
Sep 2023
$1.4m
SEED
Westminster, London, UK
Tomás Sabat
(Co-Founder & CEO)Was on the Founding Team at Vaticle, where they spent 6 years as COO. Obtained an MPhil from the University of Cambridge.
Henning Kuich
(Co-Founder & CTO)Earned a PhD in Systems Biology from Freie Universität Berlin. Spent 7 years at Bayer Pharmaceuticals, ultimately as Senior Computational Scientist.
Share this job